Cristina Mussini discusses the current data on interleukin inhibitors for the treatment of COVID-19 and explores why tocilizumab has been associated with beneficial outcomes in some studies but not others.

Medicine Matters rheumatology

Repurposing rheumatology drugs for COVID-19: Interleukin inhibitors

Marwan Bukhari talks about the rationale behind investigating baricitinib and other JAK inhibitors for the treatment of COVID-19 and outlines the current efficacy data.

Repurposing rheumatology drugs for COVID-19: JAK inhibitors

In this series of podcasts we are speaking to the experts about repurposing rheumatology drugs for the treatment and prevention of COVID-19. In this episode, Alfred (Al) Kim, a rheumatologist from the Washington University School of Medicine in St Louis, Missouri, USA, talks about hydroxychloroquine. He discusses why the drug was initially considered promising but later shown to be ineffective, and describes the impact drug shortages have had on rheumatology practice. Find more on Medicine Matters rheumatology

Repurposing rheumatology drugs for COVID-19: Hydroxychloroquine (with Alfred Kim)

In this series of podcasts we are speaking to the experts about repurposing rheumatology drugs for the treatment and prevention of COVID-19. For the introductory podcast, Jinoos Yazdany, rheumatologist and Professor of Medicine at the University of California, San Francisco in the USA, talks about the rationale behind investigating these agents and the role of rheumatologists in ensuring they are studied as safely and efficiently as possible. Find more on Medicine Matters rheumatology

Repurposing rheumatology drugs for COVID-19: What do we know?

In April 2020, the American College of Rheumatology issued guidance for the management of people with rheumatic diseases during the COVID-19 pandemic. We spoke to lead author Ted Mikuls, from the University of Nebraska Medical Center in the USA, to find out more about what rheumatologists should do to best care for their patients in light of COVID-19, and what some of the unanswered questions are. Find more on Medicine Matters rheumatology Image credit: COVID-19 illustration © koto_feja/Getty Images/iStock

A closer look at the ACR guidance on COVID-19 and rheumatology care (with Ted Mikuls)

Philip Robinson, chair of the steering committee for the COVID-19 Global Rheumatology Alliance, tells us about the initiative that will enable rheumatologists to document their patient experiences of COVID-19 and contribute to a shared learning resource (17:28). Find more on Medicine Matters rheumatology Image credit: COVID-19 illustration © koto_feja/Getty Images/iStock

The COVID-19 Global Rheumatology Alliance registry: What you need to know (with Philip Robinson)

Sangeeta Sule, from Children’s National Hospital in Washington, DC, USA, shares her experience of how the pediatric rheumatology community is adapting to the COVID-19 pandemic, including the use of telemedicine practice. Find more on Medicine Matters rheumatology

COVID-19: A pediatric rheumatologist’s perspective (with Sangeeta Sule)

Kevin Winthrop, from Oregon Health & Science University in Portland, USA, discusses why patients with rheumatic diseases may be vulnerable to COVID-19 and how different treatments may affect the risk for infection and prognosis of the disease. Find more on Medicine Matters rheumatology

COVID-19 in people with rheumatic diseases (with Kevin Winthrop)

In the second of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the implications and limitations of the recent ACR–NPF guidelines for the management of psoriatic arthritis, together with key clinical trials that have been published since the guidelines were released. Listen to part 1 here Find more on Medicine Matters rheumatology

Discussing the guidelines for managing psoriatic arthritis: Part 2 (Dafna Gladman, Philip Mease, and Oliver FitzGerald)

Lead investigator Philip Mease outlines the results of the DISCOVER-2 trial, and discusses how guselkumab may impact the psoriatic arthritis treatment landscape. Find more on Medicine Matters rheumatology More from the 2019 ACR/ARP Annual Meeting

Researcher comment: The DISCOVER-2 trial (with Philip Mease)

In the first of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the development of the recent ACR–NPF guidelines for the management of psoriatic arthritis, and the key differences between these and the EULAR and GRAPPA guidelines. Find more on Medicine Matters rheumatology Image credits: © tashatuvango/Fotolia

Discussing the guidelines for managing psoriatic arthritis: Part 1 (Dafna Gladman, Philip Mease, and Oliver FitzGerald)

Lead investigator Philip Mease discusses the findings from the SPIRIT-H2H trial, a phase III head-to-head trial of ixekizumab versus adalimumab in patients with psoriatic arthritis. Find more on Medicine Matters rheumatology This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on June 15, 2019.

Researcher comment: The SPIRIT-H2H trial (with Philip Mease)

Lead investigator Philip Mease outlines the results of a phase IIb trial supporting further development of the anti-interleukin-23p19 monoclonal antibody tildrakizumab for the treatment of psoriatic arthritis. Find more on Medicine Matters rheumatology This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on June 12, 2019.

Researcher comment: Tildrakizumab shows promise for PsA (with Philip Mease)

In this podcast, we talk to Dana DiRenzo about the benefits of physical activity in patients with rheumatic diseases, as well as tools and strategies to enable patients to be more active. Find more on Medicine Matters rheumatology This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on May 13, 2019.

Talking to patients about exercise (with Dana DiRenzo)

Antonis Fanouriakis, lead author of the updated EULAR guidelines for the management of lupus, talks to medwireNews about what’s new in these guidelines and how they will influence clinical practice. Find more on Medicine Matters rheumatology This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on May 7, 2019.

A closer look at the EULAR guidelines for managing lupus (with Antonis Fanouriakis)

Interviews with clinical experts, discussing key issues in rheumatology.

hubhopper

Medicine Matters rheumatology

hubhopper